IP Library › Granted Patent US 11,214,551
Granted Patent B2
US 11,214,551 · App. 17/050,867 · Granted Jan 4, 2022

One pot synthesis of 4-(1,2-dihydro-2-oxobenzo[d]imidazol-3-yl)butanoic acid, a key intermediate of zilpaterol

Inventors: Kannasani Ravi Kumar (Hyderabad, IN); Kasa Mallik Yadav (Hyderabad, IN); Mulu Sreenu (Hyderabad, IN); V. V. V Babu (Pulletikurru, IN)
Assignee: RA CHEM PHARMA LIMITED
C07D235/26
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,214,551
App. No.
17/050,867
Granted
Jan 4, 2022
Kind
B2
Abstract

The present invention relates to one pot process for the preparation of 4-(1,2-dihydro-2-oxobenzo[d]imidazol-3-yl)butanoic acid of Formula-I, which is a key intermediate and its use in the preparation of Zilpaterol, which comprises condensation of methyl-4-chloro butyrate with 1-(prop-1-en-2-yl)-1H-benzo[d]imidazol-2(3H)-one in presence of a base and suitable solvent to give corresponding ester derivative, further hydrolyzation and acidification in presence of inorganic solvent to obtain Formula-I.

Claims (11)

1. One pot synthesis for the preparation of 4-(1,2-dihydro-2-oxobenzo[d]imidazol-3-yl)butanoic acid of Formula-I,

which comprises:

(i) condensing methyl-4-chloro butyrate of formula-III with 1-(prop-1-en-2-yl)-1H-benzo[d]imidazol-2(3H)-one of formula II in presence of base and suitable solvent to obtain ester derivative;

(ii) hydrolyzing the above ester derivative with base and solvent to form corresponding salt; and

(iii) acidifying the above salt in presence of an acid to form 4-(1,2-dihydro-2-oxobenzo[d]imidazol-3-yl)butanoic acid of Formula-I wherein the purity of Formula-I is not less than 97% and yield is not less than 95%.

2. The process as claimed in claim 1 , wherein the solvent used in step-ii for hydrolyzing the ester derivative is essentially of water.

3. The process as claimed in claim 1 , wherein the base used in step-i is an inorganic base selected from alkali carbonates, alkali bicarbonates and alkali hydroxides.

4. The process as claimed in claim 1 , wherein the suitable solvent used in step-i is selected from the group comprising DMSO, acetonitrile, and acetic acid.

5. The process as claimed in claim 1 , wherein the base used in step-ii for hydrolyzing the ester derivative is potassium hydroxide, or sodium hydroxide.

6. The process as claimed in claim 1 , wherein step-iii acidification is carried out in presence of acid selected from hydrochloric acid, hydrobromic acid, and phosphoric acid.

7. The process as claimed in claim 1 , wherein the base used in step-i is an inorganic base selected from potassium carbonate, sodium carbonate, potassium bicarbonate, sodium bicarbonate, potassium hydroxide, and sodium hydroxide.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2024
From: RA CHEM PHARMA LIMITED
To: COHANCE LIFESCIENCES LIMITED
Reel/Frame 069632/0238 →
EMPLOYEE AGREEMENT Recorded Mar 22, 2021
From: MALLIK YADAV, KASA
To: RA CHEM PHARMA LIMITED
Reel/Frame 056555/0208 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2021
From: RAVI KUMAR, KANNASANI; SREENU, MULU; BABU, V.V.V.
To: RA CHEM PHARMA LIMITED
Reel/Frame 055663/0814 →
Priority Claims (1)
IN 201841016014 · Apr 27, 2018 · national
Continuity (1)
Related Publication 20210238146A1 · Aug 5, 2021